Review of carbapenemases and AmpC-beta lactamases

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages 1094-1095

  Marsik, Frederic J ^a   Nambiar, Sumathi ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

beta lactamases; carbapenemases; Enterobacteriaceae

Indexed keywords

AZTREONAM; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CLAVULANIC ACID; COLISTIN; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; IMIPENEM; METALLO BETA LACTAMASE; SULBACTAM; TAZOBACTAM; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; APNEA; ATAXIA; BACTERIAL GENE; CONFUSION; DIZZINESS; DRUG EFFECT; DRUG INDICATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; URINARY TRACT INFECTION; VERTIGO; VISUAL DISORDER; WEAKNESS;

BACTERIAL PROTEINS; BETA-LACTAMASES; ENTEROBACTERIACEAE;

EID: 81855185864     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823c0e47     Document Type: Review

References (14)

1. Bush K, et al. Epidemiological expansion and clinical challenges of newβ-lactamases Ann Rev Microbiol. 2011;65:455-478.
2. Gupta N, et al. Carbapenem-resistant. Enterobacteriaceae. Clin Infect Dis. 2011;53:60-67.
3. Meletis G, et al. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2011;66:946-947.
4. Falagas ME, et al. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6:653-666.
5. Yong D, et al. Characterization of a new metallo-β-lactamase gene in Klebsiella pneumoniae sequence 14 from India. Antimicrob Agents Chemother. 2009;53:5046-5054.
6. Centers for Disease Control and Prevention. Notes from the field carbapenem resistance in a clinical isolate of Providencia stuartii in a US/coalition medical facility Morb Mortal Wkly Rep. 2011;20:756.
7. Hanson ND, et al. Regulation of inducible AmpCβ-lactamase expression among Enterobacteriaceae. Curr Pharm Des. 1999;5:881-894.
8. Woodford N. Rapid characterization ofβ-lactamases by multiplex PCR. Methods Mol Biol. 2010;642:181-192.
9. Hrabak J, et al. Carbapenemase activity detection by matrix-assisted laser desorption/ionization time of flight mass spectrometry. J Clin Microbiol. 2011;49:3222-3227.
10. Turnidge JD. Cefazolin and Enterobacteriaceae: rationale for revised susceptibility testing breakpoints. Clin Infect Dis. 2011;52:917-924.
11. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement Wayne, PA: CLSI. CLSI document M100-S20-U, 2010.
12. Tamma PD, et al. Use of colistin in children. Pediatr Infect Dis J. 2009;28:534-535.
13. Souli M, et al. In vitro activity of tigecycline against multiple-drug-resistant gram-negative and gram-positive clinical isolates Antimicrob Agents Chemother. 2006;50:3166-3169. (Pubitemid 44396429)
14. Falagas ME, et al. Fosfomcyin for the treatment of extended-spectrum beta-lactamase producing, Enterobacteriaceae infections Lancet Infect Dis. 2010;10:43-50.